Cargando…

The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Montori, Giulia, Coccolini, Federico, Ceresoli, Marco, Catena, Fausto, Colaianni, Nicola, Poletti, Eugenio, Ansaloni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693/
https://www.ncbi.nlm.nih.gov/pubmed/24693422
http://dx.doi.org/10.1155/2014/912418
_version_ 1782306707062390784
author Montori, Giulia
Coccolini, Federico
Ceresoli, Marco
Catena, Fausto
Colaianni, Nicola
Poletti, Eugenio
Ansaloni, Luca
author_facet Montori, Giulia
Coccolini, Federico
Ceresoli, Marco
Catena, Fausto
Colaianni, Nicola
Poletti, Eugenio
Ansaloni, Luca
author_sort Montori, Giulia
collection PubMed
description Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 months. Different studies presented contrasting data about survival rates; however, all agreed with the necessity of a complete cytoreduction to improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has an adjuvant role in preventing peritoneal recurrences. A multidisciplinary approach should be empowered: the association of neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), cytoreductive surgery (CRS), HIPEC, and early postoperative intraperitoneal chemotherapy (EPIC) could increase the rate of completeness of cytoreduction (CC) and consequently survival rates, especially in patients with Peritoneal Cancer Index (PCI) ≤6. Neoadjuvant chemotherapy may improve survival also in PC from GC and adjuvant chemotherapy could prevent recurrence. In the last decade an interesting new drug, called Catumaxomab, has been developed in Germany. Two studies showed that this drug seems to improve progression-free survival in patients with GC; however, final results for both studies have still to be published.
format Online
Article
Text
id pubmed-3947693
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39476932014-04-01 The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art Montori, Giulia Coccolini, Federico Ceresoli, Marco Catena, Fausto Colaianni, Nicola Poletti, Eugenio Ansaloni, Luca Int J Surg Oncol Review Article Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death in the world; 53–60% of patients show disease progression and die of peritoneal carcinomatosis (PC). PC of gastric origin has an extremely inauspicious prognosis with a median survival estimate at 1–3 months. Different studies presented contrasting data about survival rates; however, all agreed with the necessity of a complete cytoreduction to improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has an adjuvant role in preventing peritoneal recurrences. A multidisciplinary approach should be empowered: the association of neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), cytoreductive surgery (CRS), HIPEC, and early postoperative intraperitoneal chemotherapy (EPIC) could increase the rate of completeness of cytoreduction (CC) and consequently survival rates, especially in patients with Peritoneal Cancer Index (PCI) ≤6. Neoadjuvant chemotherapy may improve survival also in PC from GC and adjuvant chemotherapy could prevent recurrence. In the last decade an interesting new drug, called Catumaxomab, has been developed in Germany. Two studies showed that this drug seems to improve progression-free survival in patients with GC; however, final results for both studies have still to be published. Hindawi Publishing Corporation 2014 2014-02-17 /pmc/articles/PMC3947693/ /pubmed/24693422 http://dx.doi.org/10.1155/2014/912418 Text en Copyright © 2014 Giulia Montori et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Montori, Giulia
Coccolini, Federico
Ceresoli, Marco
Catena, Fausto
Colaianni, Nicola
Poletti, Eugenio
Ansaloni, Luca
The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title_full The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title_fullStr The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title_full_unstemmed The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title_short The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
title_sort treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693/
https://www.ncbi.nlm.nih.gov/pubmed/24693422
http://dx.doi.org/10.1155/2014/912418
work_keys_str_mv AT montorigiulia thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT coccolinifederico thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT ceresolimarco thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT catenafausto thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT colaianninicola thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT polettieugenio thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT ansaloniluca thetreatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT montorigiulia treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT coccolinifederico treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT ceresolimarco treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT catenafausto treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT colaianninicola treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT polettieugenio treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart
AT ansaloniluca treatmentofperitonealcarcinomatosisinadvancedgastriccancerstateoftheart